Live News EQUITY FLASH L impact Nov 16, 2026, 10:05 PM UTC Kyntra Bio shifts strategy toward roxadustat after ending FG-3246 program Kyntra Bio presented a roxadustat-focused strategy after ending its FG-3246 program. KYNB SquawkNews Desk